Search Results - "Campa, Michael J"

Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis by Bushey, Ryan T, Gottlin, Elizabeth B, Campa, Michael J, Patz, Edward F

“…Exosomes are a class of extracellular vesicles (EVs) that are mediators of normal intercellular communication, but exosomes are also used by tumor cells to…”
Get full text

Panel of Serum Biomarkers for the Diagnosis of Lung Cancer by PATZ, Edward F, CAMPA, Michael J, GOTTLIN, Elizabeth B, KUSMARTSEVA, Irina, XIANG RONG GUAN, HERNDON, James E

“…Currently, a blood test for lung cancer does not exist. Serum biomarkers that could aid clinicians in making case management decisions would be enormously…”
Get full text

Upregulation of complement proteins in lung cancer cells mediates tumor progression by Kleczko, Emily K, Poczobutt, Joanna M, Navarro, Andre C, Laskowski, Jennifer, Johnson, Amber M, Korpela, Sean P, Gurule, Natalia J, Heasley, Lynn E, Hopp, Katharina, Weiser-Evans, Mary C M, Gottlin, Elizabeth B, Bushey, Ryan T, Campa, Michael J, Patz, Jr, Edward F, Thurman, Joshua M, Nemenoff, Raphael A

“…, cancer cells respond to signals from the tumor microenvironment resulting in changes in expression of proteins that promote tumor progression and suppress…”
Get full text

Whole Exome Sequencing of Cell-Free DNA for Early Lung Cancer: A Pilot Study to Differentiate Benign From Malignant CT-Detected Pulmonary Lesions by Tailor, Tina D, Rao, Xiayu, Campa, Michael J, Wang, Jing, Gregory, Simon G, Patz, Jr, Edward F

“…Indeterminate pulmonary lesions (IPL) detected by CT pose a significant clinical challenge, frequently necessitating long-term surveillance or biopsy for…”
Get full text

Genetic Variants of CLPP and M1AP Are Associated With Risk of Non-Small Cell Lung Cancer by Li, Xianghan, Zou, Yiran, Li, Teng, Wong, Thomas K F, Bushey, Ryan T, Campa, Michael J, Gottlin, Elizabeth B, Liu, Hongliang, Wei, Qingyi, Rodrigo, Allen, Patz, Jr, Edward F

“…Single nucleotide polymorphisms (SNPs) are often associated with distinct phenotypes in cancer. The present study investigated associations of cancer risk and…”
Get full text

Complement factor H: a novel innate immune checkpoint in cancer immunotherapy by Saxena, Ruchi, Gottlin, Elizabeth B, Campa, Michael J, Bushey, Ryan T, Guo, Jian, Patz, Jr, Edward F, He, You-Wen

“…The elimination of cancer cells critically depends on the immune system. However, cancers have evolved a variety of defense mechanisms to evade immune…”
Get full text

A Therapeutic Antibody for Cancer, Derived from Single Human B Cells by Bushey, Ryan T., Moody, M. Anthony, Nicely, Nathan L., Haynes, Barton F., Alam, S. Munir, Keir, Stephen T., Bentley, Rex C., Roy Choudhury, Kingshuk, Gottlin, Elizabeth B., Campa, Michael J., Liao, Hua-Xin, Patz, Edward F.

“…Some patients with cancer never develop metastasis, and their host response might provide cues for innovative treatment strategies. We previously reported an…”
Get full text

Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody by Winkler, Mark T, Bushey, Ryan T, Gottlin, Elizabeth B, Campa, Michael J, Guadalupe, Eross S, Volkheimer, Alicia D, Weinberg, J Brice, Patz, Jr, Edward F

“…Rituximab therapy for B cell chronic lymphocytic leukemia (B-CLL) has met with mixed success. Among several factors to which resistance can be attributed is…”
Get full text

Haptoglobin and posttranslational glycan‐modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer by Hoagland, Luke F. M., Campa, Michael J., Gottlin, Elizabeth B., Herndon, James E., Patz, Edward F.

“…BACKGROUND. The purpose was to evaluate the clinical utility of serum haptoglobin (Hp) and posttranslational glycan modifications of Hp for the diagnosis of…”
Get full text

Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth In vivo by HOWARD, Brandon A, FURUMAI, Ryohei, CAMPA, Michael J, RABBANI, Zahid N, VUJASKOVIC, Zeljko, WANG, Xiao-Fan, PATZ, Edward F

“…Cyclophilin A (CypA) was recently reported to be overexpressed in non-small-cell lung cancer, and represents a potentially novel therapeutic target. To…”
Get full text

Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis by Howard, Brandon A., Wang, Michael Z., Campa, Michael J., Corro, Christina, Fitzgerald, Michael C., Patz Jr, Edward F.

“…Many abnormalities detected in the thorax by routine conventional imaging studies are benign, yet all require further evaluation because of the concern for…”
Get full text

Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression by Wang, Yu, Sun, Sheng-Nan, Liu, Qing, Yu, Yang-Yang, Guo, Jian, Wang, Kun, Xing, Bao-Cai, Zheng, Qing-Feng, Campa, Michael J, Patz, Jr, Edward F, Li, Shi-You, He, You-Wen

“…In contrast to its inhibitory effects on many cells, IL10 activates CD8(+) tumor-infiltrating lymphocytes (TIL) and enhances their antitumor activity. However,…”
Get more information

Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103 by Bushey, Ryan T, Saxena, Ruchi, Campa, Michael J, Gottlin, Elizabeth B, He, You-Wen, Patz, Edward F

“…Development of novel therapeutic antibodies that not only kill tumor cells but modulate the adaptive immune response has the potential to produce long term…”
Get full text

Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody by Saxena, Ruchi, Bushey, Ryan T, Campa, Michael J, Gottlin, Elizabeth B, Guo, Jian, Patz, Jr, Edward F, He, You-Wen

“…Tumor-targeting Abs can be used to initiate an antitumor immune program, which appears essential to achieve a long-term durable clinical response to cancer. We…”
Get full text

Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patients by Petersen, Rebecca P., Campa, Michael J., Sperlazza, Justin, Conlon, Debbi, Joshi, Mary‐Beth, Harpole, David H., Patz, Edward F.

“…BACKGROUND. Early stage lung cancer has a variable prognosis, and there are currently no markers that predict which patients will recur. This study examined…”
Get full text

Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy by Campa, Michael J, Gottlin, Elizabeth B, Bushey, Ryan T, Patz, Jr, Edward F

“…Characterization of the humoral immune response in selected patients with cancer who uniformly do well may lead to the development of novel therapeutic…”
Get more information

Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery by Campa, Michael J., Moody, M. Anthony, Zhang, Ruijun, Liao, Hua-Xin, Gottlin, Elizabeth B., Patz, Edward F.

“…Intratumoral B lymphocytes are an integral part of the lung tumor microenvironment. Interrogation of the antibodies they express may improve our understanding…”
Get full text

Prognostic significance of a complement factor H autoantibody in early stage NSCLC by Gottlin, Elizabeth B, Campa, Michael J, Gandhi, Rikesh, Bushey, Ryan T, Herndon Nd, James E, Patz, Jr, Edward F

“…Biomarkers that predict which patients with early stage NSCLC will develop recurrent disease would be of clinical value. We previously discovered that an…”
Get more information

Complement Factor H Autoantibodies Are Associated with Early Stage NSCLC by AMORNSIRIPANITCH, Nita, SHAOLIN HONG, CAMPA, Michael J, FRANK, Michael M, GOTTLIN, Elizabeth B, PATZ, Edward F

“…To discover diagnostic biomarkers associated with early-stage non-small cell lung cancer (NSCLC), we searched for autoantibodies preferentially present in…”
Get full text

Rethinking Autoantibody Signature Panels for Cancer Diagnosis by Campa, Michael J, Gottlin, Elizabeth B, Herndon, 2nd, James E, Patz, Jr, Edward F

“…Most pulmonary nodules found on imaging studies are indeterminate, but because of the concern for lung cancer, all patients require further evaluation with…”
Get more information